CO2024004211A2 - Formulaciones de proteínas quiméricas de factor viii y usos de las mismas - Google Patents

Formulaciones de proteínas quiméricas de factor viii y usos de las mismas

Info

Publication number
CO2024004211A2
CO2024004211A2 CONC2024/0004211A CO2024004211A CO2024004211A2 CO 2024004211 A2 CO2024004211 A2 CO 2024004211A2 CO 2024004211 A CO2024004211 A CO 2024004211A CO 2024004211 A2 CO2024004211 A2 CO 2024004211A2
Authority
CO
Colombia
Prior art keywords
factor viii
formulations
chimeric factor
viii proteins
polypeptide
Prior art date
Application number
CONC2024/0004211A
Other languages
English (en)
Spanish (es)
Inventor
Tyler Carlage
Randall Mauldin
Timothy R Mccoy
Loubna Mzaalak Tazi
Original Assignee
Bioverativ Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Therapeutics Inc filed Critical Bioverativ Therapeutics Inc
Publication of CO2024004211A2 publication Critical patent/CO2024004211A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CONC2024/0004211A 2021-10-15 2024-04-04 Formulaciones de proteínas quiméricas de factor viii y usos de las mismas CO2024004211A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163256432P 2021-10-15 2021-10-15
PCT/US2022/078097 WO2023064886A1 (en) 2021-10-15 2022-10-14 Formulations of factor viii chimeric proteins and uses thereof

Publications (1)

Publication Number Publication Date
CO2024004211A2 true CO2024004211A2 (es) 2024-04-18

Family

ID=84362012

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0004211A CO2024004211A2 (es) 2021-10-15 2024-04-04 Formulaciones de proteínas quiméricas de factor viii y usos de las mismas

Country Status (13)

Country Link
US (1) US20240358800A1 (cg-RX-API-DMAC7.html)
EP (2) EP4415693B1 (cg-RX-API-DMAC7.html)
JP (1) JP2024538091A (cg-RX-API-DMAC7.html)
KR (1) KR20240082408A (cg-RX-API-DMAC7.html)
CN (1) CN118103034A (cg-RX-API-DMAC7.html)
AU (1) AU2022366974A1 (cg-RX-API-DMAC7.html)
CA (1) CA3229979A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024004211A2 (cg-RX-API-DMAC7.html)
ES (1) ES3068733T3 (cg-RX-API-DMAC7.html)
IL (1) IL311969A (cg-RX-API-DMAC7.html)
MX (1) MX2024004494A (cg-RX-API-DMAC7.html)
TW (1) TW202334244A (cg-RX-API-DMAC7.html)
WO (1) WO2023064886A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE198277T1 (de) * 1992-10-02 2001-01-15 Genetics Inst Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
KR102914074B1 (ko) 2018-05-18 2026-01-16 바이오버라티브 테라퓨틱스 인크. A형 혈우병의 치료 방법

Also Published As

Publication number Publication date
ES3068733T3 (en) 2026-06-02
JP2024538091A (ja) 2024-10-18
EP4740963A2 (en) 2026-05-13
EP4415693A1 (en) 2024-08-21
WO2023064886A1 (en) 2023-04-20
EP4740963A3 (en) 2026-07-22
CA3229979A1 (en) 2023-04-20
EP4415693B1 (en) 2026-02-18
TW202334244A (zh) 2023-09-01
KR20240082408A (ko) 2024-06-10
CN118103034A (zh) 2024-05-28
MX2024004494A (es) 2024-07-15
EP4415693C0 (en) 2026-02-18
AU2022366974A1 (en) 2024-05-30
US20240358800A1 (en) 2024-10-31
IL311969A (en) 2024-06-01

Similar Documents

Publication Publication Date Title
CO2023017358A2 (es) Formulaciones de proteínas quiméricas del factor viii y usos de las mismas
BR112023003010A2 (pt) Método de fracionamento de plasma humano, composição, e, preparações de um fator de coagulação, de igg, de um membro selecionado de a1pi, at-iii e uma combinação dos mesmos e de albumina
AR021139A1 (es) Acidos nucleicos y polipeptidos de activadores de la transcripcion y metodos de uso de los mismos
CL2021001162A1 (es) Proteínas de fusión fc il-22 y métodos de uso. (divisional de solicitud 202001944)
CO2020014566A2 (es) Métodos de tratamiento de la hemofilia a
MX9305729A (es) Formulas de proteinas de liberacion sostenida.
JOP20210084A1 (ar) البروتينات الاندماجية المتمثلة في الببتيد 1 الشبيه بالجلوكاجون (glp1) وعامل تمايز النمو 15 (gdf15) واستخدامها
DE69111440D1 (de) Methoden und zusammensetzungen zur impfung gegen hiv.
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
AR053063A2 (es) Proteina sustancialmente purificada y composicion farmaceutica que la comprende
DK250181A (da) Fremgangsmaade til fremstilling af vinblastinderivater
ES2070919T3 (es) Separacion cromatografica de las proteinas del plasma, principalmente del factor viii, del factor de willebrand de la fibronectina y del fibrinogeno.
ES2171454T3 (es) Proteinas de estres y sus usos.
CY1114244T1 (el) Σκευασματα ανταγωνιστη vegf καταλληλα για ενδοϋαλωδη χορηγηση
PE20190966A1 (es) Factor viii direccionado a los globulos rojos y metodo para su uso
BR112022005426A2 (pt) Polipeptídeos de fusão dap10/dap12
MX2024012582A (es) Composiciones farmaceuticas de proteinas terapeuticas y metodos de uso
MX2023001262A (es) Polipéptidos inhibidores del ligando 1 de muerte programada que prolongan la vida media del suero.
CO2023000048A2 (es) Conjugados de citoquina
MX2024007198A (es) Factor genetico para aumentar la expresion de las proteinas recombinantes.
MX2024004494A (es) Formulaciones de proteinas quimericas de factor viii y usos de las mismas.
MX2020003810A (es) Vacuna contra la periodontitis y composiciones relacionadas y metodos de uso.
WO2004071420A3 (en) Compositions and methods for less immunogenic protein formulations
MX2024005962A (es) Composiciones de proteínas de fusión inmunogénicas y métodos de uso de estas
MX2021016099A (es) Proteina de fusion fix mejorada y conjugar y utilizar la misma.